Estimation of the relative antiinflammatory efficacies of six commercial preparations of Harpagophytum procumbens (Devil's Claw)

Phytotherapy Research

Volumn 24, Issue 3, 2010, Pages 333-338

  Ouitas, Nassima Abdelouahab ^a   Heard, Charles ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

COX 2; Harpagophytum procumbens; Herbal remedies; Inflammation; Skin; Western blotting

Indexed keywords

8 O 4 COUMAROYL HARPAGIDE; ACTEOSIDE; CYCLOOXYGENASE 2; HARPAGIDE; HARPAGOPHYTUM PROCUMBENS EXTRACT; HARPAGOSIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CAPSULE; DRUG EFFICACY; DRUG SYNTHESIS; NONHUMAN; SWINE; TABLET FORMULATION; WESTERN BLOTTING;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; GLYCOSIDES; HARPAGOPHYTUM; PHENOLS; PHYTOTHERAPY; PLANT EXTRACTS; PYRANS; SKIN; SKIN ABSORPTION; SWINE;

HARPAGOPHYTUM PROCUMBENS; SUS;

EID: 77349091861     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2930     Document Type: Article

References (22)

1. Abdelouahab N, Heard CM. 2008a. Dermal and transcutaneous delivery of the major glycoside constituents of Harpagophytum procumbens (Devil's Claw) in vitro. Planta Med 74: 527-531.
2. Abdelouahab N, Heard CM. 2008b. Effect of the major glycosides of Harpagophytum procumbens (Devil's Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. J Nat Prod 71: 746-749.
3. Abdelouahab Ouitas N, Heard CM. 2009. A novel ex vivo skin model for the assessment of the potential transcutaneous anti-inflammatory effect of topically applied Harpagophytum procumbens extract. Int J Pharm (in press).
4. Baghdikian B, Ollivier E, Faure R, Debrauwer L, Rathelot P, Balansard G. 1999. Two new pyridine monoterpene alkaloids by chemical conversion of a commercial extract of Harpagophytum procumbens. J Nat Prod 62: 211-213.
5. Benito BP, Diaz Lanza AM, Silvan AM et al. 2000. Effects of some iridoids from plant origin on arachidonic acid metabolism in cellular systems. Planta Med 66: 324-328.
6. Betencor-Fernandez A, Perez-Galvez A, Sies H, Stahl W. 2003. Screening pharmaceutical preparations containing extracts of turmeric rhizome, artichoke leaf, devil's claw root and garlic or salmon oil for antioxidant capacity. J Pharm Pharmacol 55: 981-986.
7. Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. 1999. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized placebo-controlled double-blind study. Eur J Anaesthesiol 16: 118-129.
8. Chrubasik S, Wink M. 1998. Traditional herbal therapy for the treatment of rheumatic pain: Preparations from devil's claw and stinging nettle. Pain Digest 8: 94-101.
9. Chrubasik S, Zimpfer C, Schutt U et al. 1996. Effectiveness of Harpagophytum procumbens in the treatment of acute low back pain. Phytomedicine 3: 1-10.
10. Eich J, Schmidt M, Betti G. 1998. HPLC Analysis of iridoid compounds of Harpagophytum taxa: quality control of pharmaceutical drug material. Pharm Pharmacol Lett 8: 75-78.
11. ESCOP (European Scientific Cooperative on Phytotherapy). 2003. Devil's Claw Root. Thieme, Stuttgart, Germany.
12. European Pharmacopoeia. 2005. European Pharmacopoeia, 5th edn. Council of Europe: Strasbourg, France, 1401.
13. Fiebich BL, Heinrich M, Hiller K-O, Kammerer N. 2001. Inhibition of TNF-α synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract Steihap 69. Phytomedicine 8: 28-30.
14. Grant L, McBean DE, Fyfe L, Warnock AM. 2007. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res 21: 199-209.
15. Helliwell K. 2007. What should be identified and measured? (Quality parameters for herbal medicinal products and their ingredients). J Pharm Pharmacol 59(Suppl 1): A68-A68.
16. Loew D, Mollerfield J, Schrodter A, Puttkammer S, Kaszkin M. 2001. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and in vivo. Clin Pharmacol Ther 69: 356-364.
17. McGregor G, Fiebich B, Wartenberg A, Brien S, Lewith G, Wegener T. 2005. Devil's Claw (Harpagophytum procumbens): An anti-inflammatory herb with therapeutic potential. Phytochem Rev 4: 47-53.
18. Mestdagh O, Torck M. 1995. Quality evaluation of Harpagophytum capsules. Ann Pharm Franc 53: 135-137.
19. Moussard C, Alber D, Toubin MM, Thevenon N, Henry JC. 1992. A drug used in traditional medicine, Harpagophytum procumbens: No evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids 46: 283-286.
20. Qi J, Chen J-J, Cheng Z-H, Zhou J-H, Yu B-Y, Qiu SX. 2006. Iridoid glycosides from Harpagophytum procumbens D.C. (devil's claw). Phytochemistry 67: 1372-1377.
21. Tippler B, Syrovets T, Plaza N, Loew D, Simmet T. 1997. Harpagophytum procumbens DC used in traditional medicine inhibits eicosanoid biosynthesis in human whole blood. Int J Tissue React 19: 101-102.
22. Vickers A, Zollman C. 1999. ABC of complementary medicine - Herbal medicine. Br Med J 319: 1050-1053.